APRN Summit and Pharmacology Review

All times listed in Central Time (US & Canada).
Download event agenda (PDF)

Friday, April 13, 2018

• 12:30pm - 1:00pm

  Check-in and exhibit time

• 1:00pm - 2:30pm

  The Many Lanes of APRN Practice

  Maureen Cahill, MSN, RN, APN-CNS, Senior Policy Advisor for the National Council of State Boards of Nursing (NCSBN)
  1.5 CE Credits

• 2:30pm - 3:15pm

  APRN Consensus Model Update

  Julie Sabo PhD, RN, APRN, CNS. APRN Specialist at the Minnesota Board of Nursing
  0.75 CE Credits

  This presentation will define new regulations applicable to a licensed Minnesota APRN and discuss current regulation topics applicable to APRNs in Minnesota.

• 3:15pm - 3:30pm

  Break/Exhibitor Time

• 3:30pm - 4:30pm

  Employer Panel

  1.0 CE Credit

  Employer Representatives answer questions regarding the state of APRN practice in their respective organizations

• 4:30pm - 5:00pm

  Legislative Update

  MN APRN Coalition President Renee Dahring, MS, APRN, CNP and Vice President Brian K. Goodroad, DNP, APRN, CNP
  0.5 CE Credits

  Highlights of the 2018 legislative session and next steps

Saturday, April 14, 2018

• 8:00am - 8:15am

  Welcome

• 8:15am - 10:15am

  Opioid Prescribing: Safe Practice, Changing Lives

  Pamela Davies, MS, ARNP, A/GNP-C, ACHPN, RN-BC
  2.0 CE Credits

  This activity presented by AANP is based on the nationally vetted safe opioid prescribing standards using the FDA REMS blueprint. In addition to a robust presentation on Extended Release/Long Acting (ER/LA) opioids, our faculty will also review the nature of pain and pain management, Immediate Release/Short Acting opioids, components of an opioid trial and long term therapy, the decision to stop treatment and related issues, and the CDC Guideline for prescribing opioids for chronic pain.

• 10:15am - 10:45am

  Break/Exhibitor

• 10:45am - 11:30am

  Practical Management of Hypertension for the Busy Clinician

  Sarah Benak, MSN, APRN, CNP Mayo Clinic
  0.75 CE Credits

  At the conclusion of this presentation, participants will be able to select an appropriate medication regimen for the initial treatment of essential hypertension.

• 11:30am - 12:15pm

  What does a “LAMA" have to do with COPD?: Review of Pharmacological Therapy for COPD

  Eric Aguirre, MSN, APRN, CNP Mayo Clinic
  0.75 CE Credits

  At the conclusion of this presentation, participants will be able to:
  1) Describe the most common pharmacological treatment for COPD and related delivery devices.
  2) List 2 clinical pearls when considering pharmacological treatment for COPD.

• 12:15pm - 1:00pm

  Lunch/Exhibit

  Lunch provided. Visit exhibitor booths. Network!

• 1:00pm - 1:45pm

  Psychopharmacology for Non-Psych Prescribers

  Janelle Jones, MSN, APRN, PMHNP-BC
  0.75 CE Credits

  At the conclusion of the presentations, participants will be able to:
  1) prescribe first-line psychotropics for depression, anxiety, and bipolar disorders.
  2) describe when to continue/discontinue psychotropics and when referral to psychiatry is warranted.

• 1:45pm - 2:45pm

  CYP 450 Enzyme System

  Ruth Staus, DNP, APRN, CNP Metropolitan State University
  1.0 CE Credit

  At the conclusion of the presentation, participants will be able to:
  1) describe basic P450 function.
  2) describe the four pharmacogenomic phenotypes and their application in clinical practice prescribing.

• 2:45pm - 3:30pm

  Diabetes

  Elizabeth Nelson, MSN, APRN, CNP Mayo Clinic
  0.75 CE Credits

  At the conclusion of the presentation, participants will be able to:
  1) describe the latest ADA guidelines updates in the treatment of diabetes.
  2) list three pharmacotherapy considerations important for anti-diabetic medications.
  3) identify different programs utilized to treat type 1 and type 2 diabetes.

• 3:30pm - 4:00pm

  Break/Exhibits

• 4:00pm - 5:00pm

  Updates in Infectious Diseases: An Ambulatory Care Focus

  George Konstantinides, PharmD, BCPS, AAAHIVP and Aileen Ahiskali, PharmD are pharmacists at Hennepin Healthcare- HCMC.
  1.0 CE Credit

  At the conclusion of the presentation, participants will be able to:
  1) list 2018 IDSA guideline updates for the diagnosis and treatment of Clostridium difficile infection.
  2) describe medication options appropriate for outpatient treatment of community-acquired pneumonia.
  3) describe appropriate treatment options for asymptomatic urinary tract infections and best practice therapies for relevant UTIs.